These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9814446)

  • 1. Thyroid controversy--stimulating antibodies.
    Davies TF; Roti E; Braverman LE; DeGroot LJ
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3777-85. PubMed ID: 9814446
    [No Abstract]   [Full Text] [Related]  

  • 2. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current topics on immunological laboratory tests-thyroid diseases].
    Iwatani Y
    Rinsho Byori; 2004 Sep; 52(9):751-8. PubMed ID: 15552935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor.
    Morgenthaler NG; Pampel I; Aust G; Seissler J; Scherbaum WA
    Horm Metab Res; 1998 Mar; 30(3):162-8. PubMed ID: 9566861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.
    Hirooka Y; Li C; Takagi J; Gotoh M; Habu S; Yasaka-Nomura T; Ishihara R; Nakasone Y; Nakamura R; Morikawa R; Otake K; Nogimori T; Ishizuki Y
    Int J Clin Pharmacol Res; 2004; 24(4):111-6. PubMed ID: 15754915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of assays for TSH-receptor antibodies.
    Bitcon V; Donnelly J; Kiaei D
    J Endocrinol Invest; 2016 Oct; 39(10):1195-6. PubMed ID: 27531172
    [No Abstract]   [Full Text] [Related]  

  • 8. [Anti-TSH receptor antibody (TBII, TSAb)].
    Amino N; Kubota S
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():277-9. PubMed ID: 16149508
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A; Ciechanek R
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyethylene glycol increases the detection of anti-thyrotropin receptor antibodies by a radioreceptor assay.
    Watanabe Y; Tada H; Hidaka Y; Takano T; Takeoka K; Fukata S; Kuma K; Amino N
    Clin Chem; 1999 Mar; 45(3):407-9. PubMed ID: 10053044
    [No Abstract]   [Full Text] [Related]  

  • 12. Authors' reply.
    Kahaly GJ; Diana T
    J Endocrinol Invest; 2016 Oct; 39(10):1197-8. PubMed ID: 27531171
    [No Abstract]   [Full Text] [Related]  

  • 13. A coated tube assay for the detection of blocking thyrotropin receptor autoantibodies.
    Minich WB; Lenzner C; Bergmann A; Morgenthaler NG
    J Clin Endocrinol Metab; 2004 Jan; 89(1):352-6. PubMed ID: 14715871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of functionally different types of pathological autoantibodies against thyrotropin receptor in Graves' patients sera by luminescent immunoprecipitation analysis.
    Minich WB; Loos U
    Exp Clin Endocrinol Diabetes; 2000; 108(2):110-9. PubMed ID: 10826518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of autoantibodies directed against TSH-R.
    Rocchi R
    MLO Med Lab Obs; 2005 Apr; 37(4):10-1, 14-5; quiz 16-7. PubMed ID: 15895773
    [No Abstract]   [Full Text] [Related]  

  • 19. [Spontaneous hypothyroidism in 4 patients with Graves-Basedow disease].
    González-González A; Recio Cordova JM; Aznar Ondoño I; Del Monte Jarabo Bueno M
    Endocrinol Nutr; 2009 May; 56(5):273-6. PubMed ID: 19627750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy.
    Kung AW; Lau KS; Kohn LD
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3647-53. PubMed ID: 11502791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.